semaglutide
Semaglutide 503B Will Change by 2026 Budget or Burden?
By 2026, semaglutide’s 503B status could raise out-of-pocket costs by up to 30% for uninsured patients, yet bulk compounding may also trim expenses for insurers. The FDA’s proposed list exemption aims to balance safety with affordability, potentially reshaping how weight-loss drugs hit the market. Medical Disclaimer: This article